PDCT-02. COMBINED INHIBITION OF MTORC1/C2 AND MEK PATHWAY IS SYNERGISTIC IN PRECLINICAL TESTING OF PEDIATRIC LOW-GRADE GLIOMA INCLUDING A NOVEL PATIENT-DERIVED NF1 PILOCYTIC ASTROCYTOMA CELL LINE
Antje Arnold(Johns Hopkins University), Eric H. Raabe(Johns Hopkins University), Charles G. Eberhart(The University of Texas MD Anderson Cancer Center), Fausto J. Rodríguez(Unknown), Ming Yuan(Johns Hopkins University)
Cited by 0
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations
|Science|2011|1.1k
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711